3-amido-2-oxazolidinone derivative hapten and method for preparing same

Abstract

The invention discloses a 3-amino-2-oxazolidone derivative, namely, haptene and the preparation method thereof. The 3-amino-2-oxazolidone derivative haptene is a product of the condensation of the 3-amino-2-oxazolidone and benzaldehyde derivative with carboxyl, namely, ammonia aldehyde. The invention aims at the 3-amino-2-oxazolidone derivative, the haptene is similar to a 3-amino-2-oxazolidone derivative antimer on a molecular structure, stereochemistry and electronic distribution. Spacer arms in the haptene structure are uneasy to induce and generate an arm antibody, a saturated carbon chain with certain length is also used, and thus the organism can be more easily identified. Haptene molecules are provided with active groups convenient to be coupled with a protein carrier, and the existence of the active groups has no influence on the electronic distribution of the molecules of a substance to be measured. After the haptene is coupled with carrier protein, an antibody which has highpotency and good specificity and aims at the 3-amino-2-oxazolidone derivative can be generated by the organism.

Description

3-amino-2-oxazolidinone derivative hapten and its preparation method technical field The invention belongs to the technical field of immunology, and in particular relates to a 3-amino-2-oxazolidinone derivative hapten and its preparation technology. Background technique Furazolidone, also known as furazolidone, is a nitrofuran drug, a broad-spectrum antibiotic, and has certain antibacterial effects on Gram-positive and negative bacteria. Due to its low price and good antibacterial effect, furazolidone is widely used in the prevention and treatment of poultry, livestock, and aquatic dysentery, enteritis, coccidiosis, and turkey blackhead. However, relevant studies have proved that nitrofuran drugs and their metabolites have considerable toxicity, teratogenic side effects, and can induce cancer, which has attracted people's attention. In July 1990, the European Union promulgated Regulation 2377 / 90 / EEC, which listed nitrofuran drugs and their metabolites as Class A prohibite...

Images